Chimeric Antigen Receptor-T Cell Therapy / 대한내과학회지
Korean Journal of Medicine
;
: 229-237, 2022.
Article
in Korean
| WPRIM
| ID: wpr-938673
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS